Target ValidationApril 2026
CD74 Inhibitor Improves Memory in Alzheimer's Model — Preclinical Validation of the MIF/CD74 Axis
A new study demonstrates that DRhQ, a competitive CD74 inhibitor that blocks MIF binding, improves short-term memory and mitochondrial function in 5xFAD mice. Treatment reduced neuroinflammation, enhanced anti-inflammatory microglia, and improved antioxidant response.
JFInnova Perspective
DRhQ pharmacologically validates the same target as JFIN-0001: competitive blockade of MIF/CD74. While DRhQ is a peptide/protein construct, JFIN-0001 is a 12.6 kDa VHH nanobody engineered for greater stability, BBB penetration, and half-life — the natural therapeutic evolution of this validated mechanism.
References
1
The CD74 inhibitor DRhQ improves short-term memory and mitochondrial function in 5xFAD mouse model of Aβ accumulation
Metabolic Brain Disease · 2025
2
Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease
Molecular and Cellular Neuroscience · 2008
CD74 DRhQ Alzheimer memory MIF